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the subchondral bone plate shapes’ curvatures were mapped back to the
reference atlas space and were compared point by point to the correspond-
ing curvatures in the atlas. Once all curvatures measurements were mapped
on the atlas space they were compared to the baseline measurement doing
a point by point subtraction. Changes in curvature values from baseline
were statistically described by mean, variance and percentiles of changes
for each subject. The quantiﬁcation was done on the cMF, cLF, MT, T, F and
the entire tibio-femoral joint (TF). The paired KL scores of the 133 subjects
provided by the OAI site (http://www.oai.ucsf.edu) were used to identify
the subjects with no radiological evidence of OA (KL< 2). The longitudinal
data was analyzed using generalized least squares adjusted to JSN score
and height with a covariance structure grouped by subject and time as
continuous covariate. Furthermore, the proportion of subjects that changed
curvature metrics from 12 month to the 24 month was reported.
Results: From the 133 analyzed subjects, 18 subjects meet the analysis
criteria (KL<2). Table 1 shows the results of the quantitative analysis of
change in curvature.
Table 1. The annualized change, the standard deviation of the residuals, the annualized
standard response of the mean (SRM) and the proportion of subjects that changed mea-
surement from the 12 month to the 24 month
*Statistically different from zero (p<0.05). **Statistically different from 0.5 (p<0.05).
Conclusions: The results of this pilot study demonstrate statistically sig-
niﬁcant changes in the subchondral bone plate curvature in subjects with
clinical symptoms but no plain radiographic evidence of OA. The large
annual SRM (>0.8) observed for some biomarkers suggests that small
clinical trials can be used to test the eﬃcacy of physical or pharmaceutical
therapies aimed at preventing, halting or reversing the subchondral bone
changes associated with OA.
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PROTEOMIC ANALYSIS OF THE SECRETOME IN AN EXPLANT MODEL OF
CANINE ARTICULAR CARTILAGE
K.L. Hillier1, J. Smith2, D. Allaway3, S. Liddell1, A. Mobasheri1
1Univ. of Nottingham, Sutton Bonington, United Kingdom; 2Bruker UK Limited,
Coventry, United Kingdom; 3WALTHAM Ctr. for Pet Nutrition,
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Purpose: The aim of this study was to use high throughput proteomics
to identify the major proteins present in the secretome of an explant
model of canine articular cartilage and gain a fundamental understanding
of the proteome response to pro-inﬂammatory cytokines and non-steroidal
anti-inﬂammatory drugs.
Methods: We established an explant model of canine articular cartilage
from the stiﬂe joints of three German shepherd dogs euthanized for pur-
poses other than research. Three full depth cartilage discs were exercised
using a 3 mm biopsy punch and washed with PBS (containing 10% peni-
cillin and streptomycin). Explants were pre-incubated in serum-free DMEM
Abstract 121 – Table 1. Proteins identiﬁed in the secretome of canine cartilage using high-throughput proteomics
Protein Name Database Entry MASCOT Score Number of Peptides Functional Role
Cartilage oligomeric matrix protein precursor gi|73985933 1339 83 Structural integrity of ECM
Fibronectin 1 isoform 1 gi|74005698 1326 43 Matrix organisation
Aggrecan core protein precursor gi|12644429 1122 120 Compression resistance within the ECM
Chondroadherin precursor gi|73966365 470 15 Promotes attachment of ECM components
Matrix metalloproteinase 3 gi|50950195 500 21 Fibronectin degradation
Clusterin gi|50979240 451 11 ECM component
Decorin gi|50979008 310 16 Fibril formation within ECM
Thrombospondin-4 gi|311626 244 14 Cell-matrix interactions
Cartilage intermediate layer protein gi|74000887 186 6 Cartilage matrix organization
Biglycan gi|50979010 215 7 Collagen ﬁbre assembly
supplemented with 2% penicillin and streptomycin in a CO2 incubator
for 24 hours at 37°C. The explants were then incubated alone (control
media), or with recombinant canine IL-1β (10ng/ml), the non-steroidal
anti-inﬂammatory drug carprofen (Rimadyl, 1 mg/ml) or carprofen and IL-
1β combined (1 mg/ml and 10ng/ml respectively). After 5 days in culture,
cell-free supernatants were removed and three representative samples
were chosen from each treatment for proteomic analysis. Tryptic peptides
were separated on a 15 cm C18 PepMap™ column (LC packings) on a Bruker
Easy-nLC chromatography platform and detected in a Bruker amaZon ETD
ion trap instrument. The ﬁve most abundant peptides in each MS survey
scan were selected for fragmentation. Using the MASCOT search engine
the fragment patterns for each peptide were compared to the mammalian
entries in both the NCBInr and SwissProt databases. The modiﬁcations
incorporated into the search were: ﬁxed carbamidomethyl cysteine and
variable oxidation of methionine. In addition, the other parameters set
were: one missed cleavage site, one C13 and 0.5 Da for both MS and MS-MS
spectra.
Results: A number of cartilage-speciﬁc extracellular matrix proteins were
identiﬁed from the canine explant supernatants (Table 1). These in-
cluded cartilage oligomeric matrix protein (COMP), ﬁbronectin, biglycan,
chondroadherin precursor, matrix metalloproteinase 3, clusterin, decorin,
thrombospondin-4, cartilage intermediate layer protein CILP) and aggre-
can core protein precursor. These secreted proteins have previously been
identiﬁed in equine explant cultures in our laboratory.
Conclusions: This proteomic study has conﬁrmed the presence of a similar
set of proteins in the secretomes of canine and equine cartilage explant
models. Many of the proteins identiﬁed have well-established extracel-
lular matrix functions and are associated with matrix organisation and
cell-matrix interactions. The expression of some of the proteins identiﬁed
using this approach has been validated in equine explant supernatants
by quantitative western blotting. High-throughput proteomic analysis has
enabled detection of protein proﬁles within the secretome of a canine
cartilage explant model, similar to those in our equine explants studies. The
data presented supports the view that using high throughput proteomics
may be a useful strategy for studying dynamic changes in the secretome of
cartilage explants from species of interest in response to pro-inﬂammatory
cytokines, anti-inﬂammatory compounds and nutraceutical compounds
derived from non-protein sources.
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Purpose: In healthy cartilage there is a balance between synthesis and
degradation of extra cellular matrix components. In diseases such as OA
and in knee injuries this balance is disturbed and proteolytic cleavage of
aggrecan is seen as an early key event. Matrix metalloproteases (MMPs) and
aggrecanases are the major enzymes known to be involved in this degra-
dation. To understand the process of cartilage degradation it is important
to know where and in which preferred order the involved enzymes cleaves
aggrecan. This study was undertaken to investigate the time dependent
degradation of human aggrecan by MMP-3.
Methods: Human aggrecan was puriﬁed from a pool of adult knee OA
cartilage (n=10, from knee replacement surgery), from young (n=1) knee
healthy cartilage and from a pool of OA synovial ﬂuid (SF, n=47) by
guanidine extraction and CsCl density gradient centrifugation. Aggrecan
from OA cartilage (470 pmol) was digested by recombinant human MMP-3
(160 pmol) for up to 24h at 37°C. Samples were deglycosylated, sepa-
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rated by SDS-PAGE, transferred to PVDF membranes, and probed by FFGV
(BC-14), IPEN and TEGE neoepitope antibodies, and by antibodies against
aggrecan G1 and G3 domains. Immunodetected aggrecan fragments were
quantiﬁed using chemiluminescence and digital luminescence imager. N-
and C-terminal ends not veriﬁed by immunodetection where estimated
using a calculation model.
Results: The Western blot results showed that MMP-3 cleaves aggrecan in
several sites in six separate regions (a–f, Fig. 1). Time dependent kinetic
studies showed that the most preferred MMP cuts in aggrecan were in
region a, e and f. The second most preferred cut occurred in region d,
while cuts in region b and c were the least preferred. Also, in both young
(knee healthy) and adult (OA) cartilage, Western blot quantiﬁcation of the
in vivo MMP-generated G1-IPEN fragment was 3 times lower (mol/mol)
compared to the in vivo aggrecanase generated G1-TEGE fragment. Except
for the common G1-IPEN other fragments were detected in cartilage in vivo
(G1-CS1, 210-245 kDa) and in OA synovial ﬂuid (ARGS-CS1, 130-160 kDa;
CS1-KEEE 125 kDa) with suggested N- and C-terminals from MMP cuts in
the CS1 region.
Figure 1. Several MMP cleavage sites were found in six regions (a–f) in human aggrecan.
OA cartilage (A1D1) was in vitro digested by MMP-3 and fragments were visualized by
Western blot. Illustration of human aggrecan, MMP cleavage sites and MMP-3 in vitro
generated fragments (Mw in kDA).
Conclusions: There are at least 24 potentially MMP cleavage sites in the
CS1 domain but our results suggest that only a few sites, in the beginning
and in the end of this domain, are available for MMP proteolysis. Two of
the MMP cuts, in the IGD and in the KS region, results in loss of most of the
glycosaminoglycans from aggrecan and thereby loss of cartilage resilience.
Quantiﬁcation of in vivo generated G1-IPEN and G1-TEGE fragments indi-
cate signiﬁcant contribution of MMP proteolysis against aggrecan in both
young (knee healthy) and adult (OA) cartilage.
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Purpose: Molecules that are released into biological ﬂuids during matrix
metabolism and/or cellular activity in articular cartilage, subchondral bone,
and synovial tissue could serve as biochemical markers of the process of
osteoarthritis (OA). Unfortunately, actual breakthroughs in the biochemical
OA marker ﬁeld are limited so far. Critical evaluation of knowledge on the
performance of currently available biochemical OA markers could guide
and stimulate further biochemical OA marker research. Therefore, biochem-
ical OA marker performance was systematically reviewed according to the
“BIPED” classiﬁcation, as published in 2006 in O&C.
Methods: PubMed, Scopus and EMBASE were systematically searched for
publications on blood and urinary biochemical markers in human primary
knee and hip OA. 84 relevant publications were identiﬁed. Data were
scored and tabulated according to the “BIPED” classiﬁcation.
Results: 26 biochemical OA markers were scored according to the “BIPED”
classiﬁcation structure. Comparison of individual biochemical marker per-
formance was hampered by an uneven distribution of “BIPED” scores;
uCTX-II and sCOMP were investigated most extensively. Also, studies
showed heterogenic designs. The majority of studies involved relatively
small cohorts and/or a cross-sectional design. Therefore, comparison of
categories of biochemical markers was performed instead. Biochemical
markers of cartilage degradation were investigated most extensively and
performed well in comparison with other categories. Biochemical mark-
ers of bone metabolism performed less adequately. Biochemical markers
of synovial tissue activity were investigated minimally, but performed
relatively well.
Conclusions: This systematic review shows that there is a lack of consis-
tent, high-quality evidence for the vast majority of commercially available
biochemical OA markers. This lack of interest for some of the markers is not
necessarily supported by publications showing their limited applicability.
Additional investigation of biochemical OA markers in large-scale and/or
longitudinal cohort studies is crucial to increase our knowledge on the
applicability of these markers. Importantly, also the nature, origin and
metabolism of biochemical markers need further investigation. Interna-
tional standardization of such future investigations should be pursued
to obtain more high-quality, homogenous data on the full spectrum of
biochemical markers. Finally, all involved parties should realize that most
biochemical markers are still in an explorative stage and publication bias is
therefore undesirable and should be prevented.
This study was funded by CHECK (Cohort Hip & Cohort Knee), an initiative
of the Dutch Arthritis Association.
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Purpose: To explore prognostication of incident radiographic osteoarthritis
(OA) at the knee with OA-related biomarkers: cartilage oligomeric ma-
trix protein (COMP), hyaluronan (HA), high-sensitivity C-reactive protein
(hsCRP), and keratan sulfate (KS) in a large, community-based sample.
Methods: Baseline serum biomarkers of COMP,and KS were measured
using in-house sandwich enzyme linked immunosorbent assays, HA was
measured with the Hylauronic Acid Test kit, and hsCRP was measured with
the UBI Magiwel Enzyme Immunoassay for 803 participants recruited from
1991-1997 in the Johnston County Osteoarthritis Project. Follow-up assess-
ments were completed from 1999-2003 (mean = 6.3 years; range= 3.0 - 10.2
years). Linked baseline and follow-up anterior-posterior radiographs with
weight-bearing and footmat positioning were read for Kellgren-Lawrence
(KL) grade (0-4) and osteophyte (OST) and joint space narrowing (JSN;
both 0-3 with Burnett atlas). Three incident radiographic OA outcomes
were explored and deﬁned as: 1) a KL grade of 0-1 at baseline and ≥2 at
follow-up, 2) an OST grade=0 at baseline and ≥1 at follow-up, and 3) a
JSN grade=0 at baseline and ≥1 at follow-up. Five hundred forty two knees
were at risk for incident OA by KL grades (KL grade of 0-1 at baseline),
349 knees at risk for incident OST formation (OST=0 at baseline), and
440 knees at risk for incident JSN (JSN=0 at baseline). For each outcome,
Cox regression models were used to estimate the hazard ratio (HR) for
a 1-unit increase in the natural log of each biomarker, adjusting for age,
race, gender, and body mass index and accounting for bilateral clustering
of knees using robust variance estimates. History of lower extremity injury
(knee or hip injury or fracture) and chronic knee symptoms were explored
as potential modiﬁers of the association.
Results: In adjusted models, the hazard of incident knee OA by KL and
OST increased with higher baseline lnCOMP levels (adjusted HR [aHR]
= 1.46, 95% conﬁdence interval [CI] = 0.96-2.23, and aHR= 2.26, 95% CI
=1.45-3.53, respectively). The hazard of incident knee JSN also increased
with higher lnCOMP levels (aHR=2.14, 95% CI= 1.32-3.47) and higher lnHA
levels (aHR=1.63, 95% CI= 1.26-2.12). In unstratiﬁed analyses, higher levels
of lnhsCRP and lnKS did not predict the incident knee outcomes. Neither
history of lower extremity injury nor chronic knee symptoms was a strong
modiﬁer of these associations (p > 0.10). However, a pattern was observed
of higher adjusted HRs for lnCOMP, lnHA, and, most notably, for lnKS with
